The International Myeloma Foundation (IMF) sponsored a Corporate Friday Symposium preceding the 46th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The symposium was held on December 3, 2004, at 6:00 p.m. Pacific Time at the San Diego Marriott Hotel and Marina.
The CME-certified symposium entitled, “Controversies in Myeloma Management: Diagnosis, Initial Treatment, and the Relapsing Patient” was jointly sponsored by the IMF and the Institute for Continuing Healthcare Education, an ACCME-accredited provider of continuing medical education. The meeting co-chairmen were Bart Barlogie, MD, PhD, (University of Arkansas for Medical Science) and Brian G.M. Durie, MD, (Cedars-Sinai Comprehensive Cancer Center).
LEARNING OBJECTIVES
At the conclusion of this symposium, attendees will be able to do the following:
- Define categories of patients who are appropriate candidates for selected types of first-line myeloma therapy based on appropriate staging criteria.
- Compare the value of newer forms of remission-induction therapy to previous standards of care (melphalan + prednisone).
- Assess therapeutic options for patients in first relapse, based on their first-line therapy and their response to that therapy.
- Identify the appropriate forms of supportive care for newly diagnosed or newly relapsed patients.
- Evaluate the role of recent surgical techniques in the maintenance of spinal integrity.
TARGET AUDIENCE
This symposium has been designed to meet the educational needs of hematologists, hematologic oncologists, and other physicians treating patients with multiple myeloma.
CASE STUDY EXAMPLE
- 59-year-old woman presented with right-sided pain/right clavicular fracture.
- Needle biopsy of clavicular mass showed kappa clonal plasma cells.
- Bone marrow revealed 10% plasma cells with aggregates.
- Serum protein was negative for monoclonal protein and hypergammaglobulinemia.
- 24-hour urine protein was <150 mg.
- A diagnosis of multiple myeloma was established.
How would you stage this patient, and what would you recommend as first-line therapy?
ACCREDITATION
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of the Institute for Continuing Healthcare Education and the International Myeloma Foundation. The Institute for Continuing Healthcare Education is accredited by the ACCME to provide continuing medical education for physicians.
The Institute for Continuing Healthcare Education designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she spent in the activity.
The American Medical Association has determined that physicians not licensed in the United States who participate in this CME activity are eligible for AMA PRA category 1 credit.
PROGRAM CO-CHAIRS
 | Bart Barlogie, MD, PhD
University of Arkansas for Medical Sciences
Myeloma and Transplantation Research Center
Little Rock, Arkansas |
 | Brian G. M. Durie, MD
Cedars-Sinai Comprehensive Cancer Center
Los Angeles, California |
FACULTY
| Sigurd H. Berven, MD
University of California, San Francisco
San Francisco, California |
 | James D. Cavenagh, MD
St Bartholomew’s Hospital
London, England |
 | Morie A. Gertz, MD
Mayo Clinic College of Medicine
Rochester, Minnesota |
 | Heinz Ludwig, MD
Wilhelminen Hospital
Vienna, Austria |
 | Gareth J. Morgan, MD
The Royal Marsden Hospital
Sutton, Surrey, England |
| AGENDA |
6:00 pm Registration and Reception • 6:30 pm Program
|
| Preliminary Agenda | |
| 6:30–6:35 pm | Introductory Remarks
Bart Barlogie, MD, PhD |
| 6:35–6:55 pm | Preliminary Case Evaluation: An Interactive Assessment of Audience Treatment Opinions on 4 Cases
Morie A. Gertz, MD |
| 6:55–7:20 pm | New Approaches to Myeloma Staging and Front-Line Treatment Selection
Brian G. M. Durie, MD |
| 7:20–7:45 pm | Current US Experience With Transplantation in the Management of the Newly Diagnosed Patient
Bart Barlogie, MD, PhD |
| 7:45–8:10 PM | Current European Experience With Transplantation in the Management of the Newly Diagnosed Patient
Gareth J. Morgan, MD |
| 8:10 – 8:35 pm | Evaluation of the Patient in Initial Relapse and Selection of Second-Line Therapeutic Options
James D. Cavenagh, MD |
| 8:35–9:00 pm | Vertebral Augmentation in the Management of Myeloma-Related Compression Fractures
Sigurd H. Berven, MD |
| 9:00–9:25 pm | Supportive Care and Management of the Newly Diagnosed and Initially Relapsing Patient
Heinz Ludwig, MD |
| 9:25–9:45 pm | Case Evaluation Revisited
Morie A. Gertz, MD |
| 9:45-10:00 pm | Audience Questions and Discussion
Brian G. M. Durie, MD |
| 10:00 pm | Close |
The IMF’s sponsorship of the symposium is part of their mandate as the oldest and largest myeloma organization in existence, reaching more than 100,000 members in 106 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients and their families through funding and creating groundbreaking research, providing education, lending support and promoting advocacy initiatives, while working toward prevention and cure.
Click here to register for this program or call 215-446-8088 ext. 1170. There is no registration fee for attending this program.
